Antivascular approaches to solid tumour therapy: Evaluation of tubulin binding agents

British Journal of Cancer

Volumn 74, Issue SUPPL. XXVII, 1996, Pages

  Chaplin, D J ^a   Pettit, G R ^b   Parkins, C S ^a   Hill, S A ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Bloodflow; Combretastatin; Dolastatin; FAA; Tirapazamine; Vinblastine

Indexed keywords

COMBRETASTATIN; DOLASTATIN; MITOFLAXONE; TIRAPAZAMINE; TUBULIN; VINBLASTINE; ANTINEOPLASTIC AGENT; BIBENZYL DERIVATIVE; DEPSIPEPTIDE; DOLASTATIN 10; DOLASTATIN 15; FLAVONOID; OLIGOPEPTIDE; STILBENE DERIVATIVE; TRIAZINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CELL KILLING; CONFERENCE PAPER; CONTROLLED STUDY; DRUG PROTEIN BINDING; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; TUMOR BLOOD FLOW; ANIMAL; ARTICLE; BIOSYNTHESIS; BLOOD FLOW; CBA MOUSE; DRUG EFFECT; EXPERIMENTAL NEOPLASM; METABOLISM; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BIBENZYLS; DEPSIPEPTIDES; FLAVONOIDS; MICE; MICE, INBRED CBA; NEOPLASMS, EXPERIMENTAL; OLIGOPEPTIDES; REGIONAL BLOOD FLOW; STILBENES; TRIAZINES; TUBULIN; TUMOR NECROSIS FACTOR-ALPHA; VINBLASTINE;

EID: 0029902597     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (21)

1. BAGULEY BC, HOLDAWAY KH, THOMSEN LL, ZHUANG L AND ZWI LJ. (1991) Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: Evidence for a vascular mechanism. Eur. J. Cancer, 27, 482-487.
2. BAI R, FRIEDMAN SJ, PETTIT GR AND HAMEL E. (1992). Dolastatin 15 a potent antimitotic depsipeptide derived from Dolabella Auricularia. Biochem. Pharmacol., 43, 2637-26465.
3. BAI R, PETTIT GR AND HAMEL E. (1990a). Dolastatin 10, a powerful cytostatic peptide derived from a marine animal: Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem. Pharmacol., 39, 1941-1949.
4. BAI R, PETTIT GR AND HAMEL E. (1990b). Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exhangeable nucleotide and vinca alkaloid sites. J. Biol. Chem., 265, 17141-17149.
5. BIBBY MC, DOUBLE JA, LOADMAN PM AND DUKE CV. (1989). Reduction of tumour blood flow by flavone acetic acid: a possible component of therapy. JNCI, 81, 216-220.
6. CHAPLIN DJ AND HORSMAN MR. (1992). Tumour blood flow changes induced by chemical modifiers of radiation response. Int. J. Radiat. Oncol. Biol. Phys., 22, 459-462.
7. CLIFFE S, TAYLOR ML, RUTLAND M, BAGULEY BC, HILL RP AND WILSON W. (1994). Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid. Int. J. Radiat. Oncol. Biol. Phys., 29, 373-377.
8. DORIE MJ AND BROWN JM. (1993). Tumour specific, schedule dependent interaction between tirapazamine (SR-4233) and cisplatin. Cancer Res., 53, 4633-4636.
9. EDWARDS HS, BREMNER JCM AND STRATFORD IJ. (1991). Induction of tumour hypoxia by FAA and TNF: Interaction with bioreductive drugs. Int. J. Radiat. Biol., 60, 373-377.
10. HILL SA, LONERGAN SJ, DENEKAMP J AND CHAPLIN DJ. (1993). Vinca alkaloids: anti-vascular effects in a murine tumour. Eur. J. Cancer, 29A, 1320-1324.
11. HILL SA, SAMPSON LE AND CHAPLIN DJ. (1995). Anti-vascular approaches to solid tumor therapy: Evaluation of vinblastine and Flavone acetic acid. Int. J. Cancer, 63, 119-123.
12. KALLINOWSKI F, SHAEFER C, TYLER G AND VAUPEL P. (1989). In vivo targets of recombinant human tumour necrosis factor blood flow, oxygen consumption and growth of isotransplanted rat tumours. Br. J. Cancer. 60, 555-560.
13. MAHADEVAN V, MALIK STA, MEAGER A, FIERS W, LEWIS GP AND HART IR. (1990). Role of tumour necrosis factor in flavone acetic acid induced vascular shutdown. Cancer Res., 50, 5537-5542.
14. PETTIT GR, SINGH SB, NIVEN ML, HAMEL E AND SCHMIDT JM. (1987). Antineoplastic agents 124. Isolation, structure and synthesis of combretstatin A1 and combretstatin B1, potent new inhibitors of microtubule assembly, derived from combretum caffrum. J. Natl Prod., 50, 119-131.
15. PETTIT GR, SINGH SB, HAMEL E, LIN CM, ALBERTS DS AND GARIA-KENDALL D. (1989). Isolation and structure of the strong cell growth and tubulin inhibitor combretstatin A4. Experientia, 45, 205-211.
16. PETTIT GR, SINGH SB, BOYD MR, HAMEL E, PETTIT RK, SCHMIDT JM AND HOGAN G. (1995). Antineoplastic agents 291. Isolation and synthesis of combretstatins A-4, A-5 and A-6. J. Med. Chem., 291, 1666-1672.
17. SAPIRSTEIN LA. (1958). Regional blood flow by fractional distribution of indications. Am. J. Physiol., 193, 161-168.
18. SUN J AND BROWN JM. (1989). The bioreductive drug SR4233 enhances the anti-tumour effect of flavone acetic acid. Cancer Res., 49, 5664-5670.
19. VESZELOVSKY E, THOMSEN LL, ZHUANG L AND BAGULEY BC. (1993). Flavone acetic acid and 5,6 Dimethyl xanthenone-4-acetic acid: Relationship between plasma nitrate elevation and induction of necrosis. Eur. J. Cancer, 29(3), 404-408.
20. WOODS JA, HADFIELD JA, PETTIT GR, FOX BW AND McGOWN AT. (1995). The interaction with tubulin of a series of stilbenes based on combretastatin A-4. Br. J. Cancer, 71, 705-711.
21. ZWI JL, BAGULEY BC, GAVIN JB AND WILSON WR. (1989). Blood flow failure as a major determinant in the anti-tumour action of flavone acetic acid (NSC 347512). J. Natl Cancer Inst., 81, 1005-1013.